Camptosar

(Irinotecan)

ApprovedSmall molecule

Irinotecan is a chemotherapy drug used to treat certain types of cancer, including colorectal cancer and small cell lung cancer, by damaging cancer cell DNA to stop them from growing.[2] Camptosar is currently approved and in use across 88 indications[4].[1]

Camptosar is one of 1079 small molecule programs targeting Small Cell Lung Cancer. It is currently in Approved.

Indications

647

Total Trials

Active Trials

1,078

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Small Cell Lung CancerCompleted

LymphomaCompleted

Ewing SarcomaActive, not recruiting

Advanced Malignant TumorsNot yet recruiting

Second-Line TreatmentRecruiting

Patients With Advanced Solid TumorsActive, not recruiting

Efficacy and SafetyCompleted

Refractory Solid TumorsRecruiting

Pancreatic CancerCompleted

Colorectal NeoplasmApproved

Small Cell Lung CancerPhase 3

Completed

LymphomaPhase 1

Completed

Ewing SarcomaPhase 2

Active, not recruiting

Advanced Malignant TumorsPhase 2

Not yet recruiting

Second-Line TreatmentPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Active, not recruiting

Efficacy and SafetyPhase 2

Completed

Refractory Solid TumorsPhase 1

Recruiting

Pancreatic CancerPhase 3

Completed

Colorectal NeoplasmApproved

Approved

Showing 10 of 88 indications

Competition

Competitive Landscape

370 competitors in Lymphoma

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Approved

2 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT03773367

Phase 2Active, not recruiting

Metastatic Colorectal Cancer

NCT06107413

Phase 3Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06351020

Phase 1Recruiting

Colon Adenocarcinoma

NCT04920032

Q1 2027

Phase 1/2Recruiting

Metastatic Colorectal Cancer

NCT04689347

Q2 2027

Phase 2Active, not recruiting

Pancreatic Cancer

NCT04481204

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer39 trials

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy

Completed· Amgen logo

Amgen·Phase 2·NCT00332163·95 enrolled

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Recruiting·AAkeso·Phase 3·NCT06951503·560 enrolled

A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan

Completed· Sanofi logo

Sanofi·Phase 2·NCT01882868·62 enrolled

Show 36 more trials

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Completed·SSun Yat-sen University·Phase 1/2·NCT04790448·37 enrolled

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Terminated· Pfizer logo

Pfizer·Phase 2·NCT01925274·19 enrolled

Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05160727·44 enrolled

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT01008475·232 enrolled

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Active, not recruiting·—·Phase 2·NCT04117945·22 enrolled

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Completed·—·Phase 2·NCT02292758·36 enrolled

Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Terminated· Gilead logo

Gilead·Phase 2·NCT05330429·77 enrolled

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Terminated· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 1/2·NCT00838578·65 enrolled

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00851045·17 enrolled

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.

Unknown status·HHôpital Franco-Britannique-Fondation Cognacq-Jay·Phase 2·NCT04189055·72 enrolled

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT02928224·702 enrolled

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00126256·570 enrolled

Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00111761·43 enrolled

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00037180·212 enrolled

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT00730158·33 enrolled

Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT00254137·92 enrolled

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Unknown status·PPeking University·Phase 2·NCT03567629·130 enrolled

A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 1·NCT00671372·42 enrolled

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

Recruiting·AAUM Biosciences Pte Ltd·Phase 2·NCT05462236·120 enrolled

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Completed·LLudwig-Maximilians - University of Munich·Phase 3·NCT02934529·673 enrolled

Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

Completed· GSK logo

GSK·Phase 1·NCT00540943·25 enrolled

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT06107413·280 enrolled

Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00230399·15 enrolled

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00483834·50 enrolled

A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00034502

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 1/2·NCT04689347·27 enrolled

ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer

Completed·—·Phase 1·NCT00436072·46 enrolled

Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients

Completed·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 2/3·NCT01523431·583 enrolled

FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients

Unknown status·FFudan University·Phase 3·NCT02935764·164 enrolled

Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

Terminated·—·Phase 2·NCT00717990·15 enrolled

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Completed·UUNICANCER·Phase 2·NCT01442649·133 enrolled

Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer

Terminated·GGeneric Devices Consulting, Inc.·Phase 1/2·NCT00816777·4 enrolled

Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00457691·768 enrolled

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Completed·OOncolytics Biotech·Phase 1·NCT01274624·36 enrolled

Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 2·NCT00233623·190 enrolled

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05160896·90 enrolled

Colorectal Cancer18 trials

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

Completed·TThe Queen Elizabeth Hospital·Phase 1/2·NCT01139138·49 enrolled

Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer

Completed·—·Phase 2·NCT00689624·30 enrolled

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT00766220

Show 15 more trials

FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 3·NCT01566942·200 enrolled

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·—·Phase 2·NCT03053167·100 enrolled

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Completed·NNektar Therapeutics·Phase 2·NCT00856375·83 enrolled

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00681876·16 enrolled

Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02414009·82 enrolled

Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer

Completed·HHokkaido Gastrointestinal Cancer Study Group·Phase 1/2·NCT00209625·23 enrolled

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05839470·20 enrolled

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Unknown status·PPD Dr. med. Volker Heinemann·Phase 3·NCT00433927·568 enrolled

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00551213·67 enrolled

SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

Terminated·MMassachusetts General Hospital·Phase 1/2·NCT00361244·6 enrolled

Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

Completed·IInstitut de Recherche Clinique sur les Cancers et le Sang·Phase 4·NCT00138060·71 enrolled

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·FFudan University·Phase 2·NCT02376452·100 enrolled

Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT03175016·200 enrolled

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00063141·1,302 enrolled

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors

Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT01858662·4 enrolled

Small Cell Lung Cancer12 trials

Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer

Completed·UUniversity of California, Davis·Phase 2·NCT00387660·80 enrolled

Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01635400·50 enrolled

SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Unknown status·BBiocity Biopharmaceutics Co., Ltd.·Phase 1/2·NCT05731518·67 enrolled

Show 9 more trials

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03879798·22 enrolled

Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer

Unknown status·TThird Military Medical University·Phase 2·NCT01977235·110 enrolled

A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Unknown status·NNational Cancer Center, Korea·Phase 1/2·NCT00874328·74 enrolled

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00294931·50 enrolled

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

Unknown status·SShengFa Su·Phase 2·NCT03613753·72 enrolled

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00308529·55 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00057837·140 enrolled

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06954246·450 enrolled

Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193349·60 enrolled

Gastric Cancer11 trials

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT01084330·68 enrolled

Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

Unknown status·FFujian Medical University·Phase 2·NCT05643677·47 enrolled

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02625623·371 enrolled

Show 8 more trials

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Completed·—·Phase 2·NCT00165464·54 enrolled

ILF With/Without Cisplatin for Advanced Gastric Cancer

Unknown status·GGachon University Gil Medical Center·Phase 2·NCT00320294·86 enrolled

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05669807·184 enrolled

Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Completed·—·Phase 2·NCT00911820·88 enrolled

Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

Completed·JJapan Clinical Cancer Research Organization·Phase 2/3·NCT00639327·300 enrolled

Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Suspended·HHokkaido Gastrointestinal Cancer Study Group·Phase 2·NCT00209664·40 enrolled

Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy

Recruiting·SShandong Tumor Hospital·Phase 2·NCT07309185·66 enrolled

Docetaxel and Irinotecan in Gastric Cancer

Completed·MMenoufia University·Phase 2·NCT04770623·32 enrolled

Pancreatic Cancer6 trials

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01821612·23 enrolled

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT01729481·150 enrolled

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed·SSWOG Cancer Research Network·Phase 1/2·NCT01959139·126 enrolled

Show 3 more trials

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04481204·105 enrolled

SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

Completed·NNational Health Research Institutes, Taiwan·Phase 2·NCT03443492·130 enrolled

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Completed·—·Phase 1/2·NCT03699319·49 enrolled

77 more indications

Esophageal Cancer5 trials

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00400114·36 enrolled

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

Completed·—·Phase 2·NCT00165490·19 enrolled

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT05342636·90 enrolled

Show 2 more trials

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03099382·457 enrolled

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Completed·—·Phase 2·NCT00137852·35 enrolled

Esophageal Squamous Cell Carcinoma5 trials

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Completed·PPeking University·Phase 1·NCT02645864·12 enrolled

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Completed·FFudan University·Phase 2·NCT03797625·52 enrolled

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03387904·120 enrolled

Show 2 more trials

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Completed· BeiGene logo

BeiGene·Phase 3·NCT03430843·512 enrolled

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Completed· Novartis logo

Novartis·Phase 1·NCT01822613·48 enrolled

Refractory Solid Tumors4 trials

A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00057473

A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00990912·20 enrolled

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06006273·48 enrolled

Show 1 more trial

Metformin in Children With Relapsed or Refractory Solid Tumors

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01528046·26 enrolled

Ewing sarcoma4 trials

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT05042934

Anlotinib and Irinotecan for Ewing Sarcoma

Unknown status·PPeking University People's Hospital·Phase 1/2·NCT03416517·47 enrolled

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Completed·SSarcoma Alliance for Research through Collaboration·Phase 1·NCT02044120·34 enrolled

Show 1 more trial

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01864109·83 enrolled

Neuroblastoma4 trials

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT04385277·41 enrolled

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT04221035·800 enrolled

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Recruiting·SSun Yat-Sen University Cancer Center·Phase 2·NCT06013618·120 enrolled

Show 1 more trial

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT00808899·4 enrolled

Efficacy and Safety3 trials

To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

Unknown status·PPeking University·Phase 2·NCT05818982·72 enrolled

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Active, not recruiting·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT05312398·219 enrolled

Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT03279289·170 enrolled

Pancreatic Adenocarcinoma3 trials

Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

Completed·TThe University of Hong Kong·Phase 2·NCT01558869·37 enrolled

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 1·NCT02620423·11 enrolled

FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Completed·WWashington University School of Medicine·Phase 1·NCT01413022·44 enrolled

Chemotherapy3 trials

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Completed·—·Phase 1·NCT02021422·13 enrolled

FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

Terminated·SSun Yat-sen University·Phase 3·NCT03678428·92 enrolled

RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting·AAustralasian Gastro-Intestinal Trials Group·Phase 3·NCT04879368·450 enrolled

Adenocarcinoma3 trials

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT07284134·560 enrolled

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02283359·3 enrolled

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00077233·238 enrolled

Biliary Tract Cancer2 trials

Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer

Unknown status·SSoon Chun Hyang University·Phase 2·NCT01494363·53 enrolled

Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

Completed·ZZhejiang University·Phase 2·NCT02558959·64 enrolled

mCRC2 trials

Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC

Withdrawn·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT01631539

Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC

Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT02339116·654 enrolled

Treatment2 trials

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT04587128·34 enrolled

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Completed· Amgen logo

Amgen·Phase 2·NCT00418938·266 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruiting·LLund University Hospital·Phase 2·NCT03773367·60 enrolled

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruiting·LLaNova Medicines Zhejiang Co., Ltd.·Phase 3·NCT06351020·387 enrolled

Esophageal Adenocarcinoma2 trials

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Completed·UUniversity of California, Irvine·Phase 1·NCT04074343·20 enrolled

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Terminated·UUNICANCER·Phase 1/2·NCT03722108·89 enrolled

Colorectal Carcinoma2 trials

CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT00969033·8 enrolled

Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma

Completed·HHiberCell, Inc.·Phase 1/2·NCT00545545·32 enrolled

Gastroesophageal Junction Cancer2 trials

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Terminated·KKuhnil Pharmaceutical Co., Ltd.·Phase 3·NCT01813253·400 enrolled

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02485834·5 enrolled

Second-line Treatment2 trials

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Recruiting·FFudan University·Phase 2·NCT05229003·44 enrolled

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

Unknown status·—··NCT06169202·50 enrolled

Glioblastoma2 trials

A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma

Completed· Roche logo

Roche·Phase 2·NCT00967330·182 enrolled

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00762255·19 enrolled

Locally-advanced Rectal Cancer2 trials

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

Terminated·—·Phase 2·NCT00216086·22 enrolled

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Unknown status·FFudan University·Phase 2·NCT04411524·50 enrolled

Bevacizumab1 trial

A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

Unknown status·JJapan Clinical Cancer Research Organization·Phase 2·NCT02515734·360 enrolled

Monotherapy1 trial

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Completed· AbbVie logo

AbbVie·Phase 1·NCT01009073·51 enrolled

Solid Malignancies1 trial

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02392793·43 enrolled

CNS Malignancies1 trial

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Unknown status·SSynerGene Therapeutics, Inc.·Phase 1·NCT03554707·6 enrolled

Central Nervous System (CNS) Tumors1 trial

Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors

Completed·JJohns Hopkins All Children's Hospital·Phase 1·NCT00876993·26 enrolled

Non-Small Cell Lung Cancer1 trial

Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

Terminated·KKentuckiana Cancer Institute·Phase 1/2·NCT00264134·40 enrolled

BRAF1 trial

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT02296203·27 enrolled

CRC1 trial

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT05217069·57 enrolled

Metastatic Cancer1 trial

A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Completed· Roche logo

Roche·Phase 2·NCT01131078·306 enrolled

Cisplatin1 trial

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Terminated·LLeo W. Jenkins Cancer Center·Phase 2·NCT02275806·4 enrolled

Patients With Solid Tumors1 trial

Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors

Completed·DDorte Nielsen·Phase 1·NCT03295084·39 enrolled

PD-1antibody1 trial

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC

Unknown status·SSun Yat-sen University·Phase 3·NCT05737563·380 enrolled

Advanced Solid Tumors1 trial

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00954512·15 enrolled

CNS Tumors1 trial

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

Completed·UUniversity of New Mexico·Phase 1·NCT00251797·10 enrolled

Desmoplastic Small Round Cell Tumor1 trial

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT04095221·21 enrolled

Trial1 trial

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

Completed·UUniversity of Southern California·Phase 1·NCT00183859·42 enrolled

Solid Tumor Cancer1 trial

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT05004116·77 enrolled

Transplantation1 trial

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Unknown status·UUniversity of Pisa··NCT03668418·120 enrolled

Colon Cancer1 trial

IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

Completed·UUNICANCER·Phase 3·NCT02967289·792 enrolled

Phase II1 trial

Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005626·10 enrolled

Relapse1 trial

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Recruiting· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 3·NCT06496048·180 enrolled

Patients With Advanced Solid Tumors1 trial

A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT05148195·86 enrolled

Colon Adenocarcinoma1 trial

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Recruiting·UUniversity of California, Irvine·Phase 1·NCT04920032·22 enrolled

Children1 trial

Study of Irinotecan on a Weekly Schedule in Children

Completed·—·Phase 1·NCT00062842·23 enrolled

Temozolomide1 trial

Study of MLN8237 in Combination With Irinotecan and Temozolomide

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1/2·NCT01601535·54 enrolled

Esophageal Carcinoma1 trial

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00590031·61 enrolled

Combination Therapy1 trial

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting·UUniversity of California, San Francisco·Phase 1·NCT05694715·24 enrolled

Recurrent or Metastatic1 trial

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

Terminated·UUniversity of California, Irvine·Phase 2·NCT00256269·4 enrolled

Metastatic1 trial

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00755534·68 enrolled

Rhabdomyosarcoma1 trial

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting·UUniversity of Birmingham·Phase 1/2·NCT04625907·1,672 enrolled

First-line Treatment1 trial

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Unknown status·FFujian Cancer Hospital·N/A·NCT03045770·150 enrolled

Solid Tumors1 trial

A Study of TXN10128 in Subjects With Solid Tumors

Recruiting·TTxinno Bioscience Inc.·Phase 1·NCT05978492·96 enrolled

RAS Mutation1 trial

Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

Completed·VVejle Hospital·Phase 2·NCT00792363·32 enrolled

Lymphoma1 trial

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Completed·CChildren's Oncology Group·Phase 1·NCT03323034·30 enrolled

Relapsed or Refractory1 trial

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Completed·UUniversity of California, San Francisco·Phase 1·NCT03139331·16 enrolled

Peritoneal Carcinomatosis1 trial

Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin

Completed·EErasmus Medical Center·Phase 1·NCT05379790·20 enrolled

Primary Brain Tumor1 trial

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Completed·RRigshospitalet, Denmark·Phase 2·NCT00463203·54 enrolled

Recurrent or Refractory Solid Tumors1 trial

A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Completed·—·Phase 1·NCT00993044·13 enrolled

Neoadjuvant1 trial

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Completed·MMassachusetts General Hospital·Phase 1·NCT03279237·25 enrolled

Hematologic Malignancies1 trial

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Completed· Takeda logo

Takeda·Phase 1·NCT02327169·81 enrolled

Cervical Cancer1 trial

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Withdrawn·AAgenus Inc.·Phase 3·NCT04943627

Vaginal Cancer1 trial

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Terminated·WWomen and Infants Hospital of Rhode Island·Phase 2·NCT00106262·38 enrolled

Colorectal Adenocarcinoma1 trial

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Terminated· Gilead logo

Gilead·Phase 2·NCT01479465·266 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Active, not recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT06625320·501 enrolled

Rectal Carcinoma1 trial

Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma

Completed·WWashington University School of Medicine·Phase 2·NCT00682786·135 enrolled

Soft Tissue Sarcoma1 trial

Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT01380275·35 enrolled

First Line Therapy1 trial

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Withdrawn·FFujian Cancer Hospital·Phase 2·NCT03222089

Wilms tumor1 trial

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Recruiting·CCentre Oscar Lambret·Phase 1/2·NCT05384821·28 enrolled

Malignant Glioma1 trial

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Completed·—·Phase 2·NCT00352521·20 enrolled

Pediatric Solid Tumors1 trial

A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

Completed·—·Phase 1·NCT00786669·13 enrolled

TED1 trial

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01116271·32 enrolled

Neuroendocrine Tumor1 trial

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03963193·112 enrolled

Tics1 trial

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

Completed· Amgen logo

Amgen·Phase 1·NCT00563316·28 enrolled

Neuroendocrine Carcinoma1 trial

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Completed·UUniversity of California, San Francisco·Phase 2·NCT03136055·36 enrolled

Breast Cancer1 trial

Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

Completed· Pfizer logo

Pfizer·Phase 2·NCT00072852·134 enrolled

Intraperitoneal1 trial

Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT03061058·240 enrolled

Toxicity1 trial

Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01859858·23 enrolled

Unspecified3 trials

A Study of Mitomycin C, Irinotecan, and Cetuximab

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00271011·13 enrolled

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

Unknown status·FFudan University·Phase 2·NCT04833036·120 enrolled

Resection Observatory

Completed· Sanofi logo

Sanofi··NCT05178745·140 enrolled

Regulatory

FDA Approval Timeline[5]

Jun 14, 1996

CAMPTOSAR

NDA NDA020571

Jun 14, 1996

CAMPTOSAR

NDA NDA020571

Mar 7, 1997

CAMPTOSAR

NDA NDA020571

Jun 5, 1997

CAMPTOSAR

NDA NDA020571

Oct 21, 1997

CAMPTOSAR

NDA NDA020571

Dec 10, 1997

CAMPTOSAR

NDA NDA020571

Jan 15, 1998

CAMPTOSAR

NDA NDA020571

Mar 18, 1998

CAMPTOSAR

NDA NDA020571

Oct 22, 1998

CAMPTOSAR

NDA NDA020571

Apr 20, 2000

CAMPTOSAR

NDA NDA020571

Jul 29, 2000

CAMPTOSAR

NDA NDA020571

Aug 6, 2001

CAMPTOSAR

NDA NDA020571

Nov 5, 2001

CAMPTOSAR

NDA NDA020571

May 16, 2002

CAMPTOSAR

NDA NDA020571

Jul 30, 2002

CAMPTOSAR

NDA NDA020571

Jun 24, 2004

CAMPTOSAR

NDA NDA020571

Dec 3, 2004

CAMPTOSAR

NDA NDA020571

Jun 7, 2005

CAMPTOSAR

NDA NDA020571

Jul 21, 2005

CAMPTOSAR

NDA NDA020571

Jul 21, 2005

CAMPTOSAR

NDA NDA020571

Jul 21, 2005

CAMPTOSAR

NDA NDA020571

Aug 1, 2006

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

Jul 13, 2012

CAMPTOSAR

NDA NDA020571

Jan 17, 2013

CAMPTOSAR

NDA NDA020571

Jun 9, 2014

CAMPTOSAR

NDA NDA020571

Dec 19, 2014

CAMPTOSAR

NDA NDA020571

Oct 22, 2015

ONIVYDE

NDA NDA207793

Feb 22, 2019

CAMPTOSAR

NDA NDA020571

Jan 30, 2020

CAMPTOSAR

NDA NDA020571

Jan 27, 2022

CAMPTOSAR

NDA NDA020571

Jan 27, 2022

CAMPTOSAR

NDA NDA020571

Apr 4, 2024

CAMPTOSAR

NDA NDA020571

Sources

References

[1]
ClinicalTrials.gov — 647 trial records for Irinotecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Camptosar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Irinotecan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Irinotecan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020571). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Camptosar. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase I Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Patent Landscape[6]

Patent Cliff

Jan 6, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8329213Jan 6, 2027

8147867Aug 29, 2028

9364473Jun 12, 2033

12364691Jun 12, 2033

11369597Jun 12, 2033

9 more patents

9339497Jun 12, 2033

9452162Jun 12, 2033

10980795Jun 12, 2033

9717724Jun 12, 2033

9492442Jun 12, 2033

11344552Aug 19, 2036

12059497Oct 15, 2036

10456360Oct 15, 2036

10993914Oct 15, 2036